Corcept Therapeutics (CORT) EBITDA Margin (2012 - 2026)
Corcept Therapeutics (CORT) reported EBITDA Margin of 30.08% for Q1 2026, down 3225.0% on a YoY basis from 0.96% in Q1 2025, and down 1454.96% sequentially from 2.22% in Q4 2025.
Corcept Therapeutics (CORT) EBITDA Margin (2012 - 2026) Analysis & Trends
Corcept Therapeutics (CORT) has 15 years of EBITDA Margin data on file, last reported at 30.08% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 3225.0% year-over-year to 30.08%; the trailing twelve-month figure through Mar 2026 stood at 1.07% (down 1724.0% YoY), and the FY2025 full-year result was 5.88%, down 1440.0% from the prior year.
- EBITDA Margin slipped to 30.08% in Q1 2026, from 2.22% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 31.39% in Q3 2022 to a low of 30.08% in Q1 2026.
- A 5-year average of 16.13% and a median of 21.73% in 2024 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin soared 604 bps in 2024 and tumbled 3225 bps in 2026, its largest moves.
- Tracing CORT's EBITDA Margin over 5 years: stood at 21.83% in 2022, then advanced by 7 bps to 23.39% in 2023, then sank by 41 bps to 13.89% in 2024, then slumped by 84 bps to 2.22% in 2025, then sank by 1455 bps to 30.08% in 2026.
- Business Quant data shows CORT's EBITDA Margin at 30.08% in Q1 2026, 2.22% in Q4 2025, and 4.92% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Corcept Therapeutics | 9.99 Bn | 9.65 Bn | 162.02 Mn | -30.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.08% |
| Dec 31, 2025 | 2.22% |
| Sep 30, 2025 | 4.92% |
| Jun 30, 2025 | 13.72% |
| Mar 31, 2025 | 2.17% |
| Dec 31, 2024 | 13.89% |
| Sep 30, 2024 | 25.53% |
| Jun 30, 2024 | 21.73% |
| Mar 31, 2024 | 20.09% |
| Dec 31, 2023 | 23.39% |
| Sep 30, 2023 | 25.22% |
| Jun 30, 2023 | 25.13% |
| Mar 31, 2023 | 14.06% |
| Dec 31, 2022 | 21.83% |
| Sep 30, 2022 | 31.39% |
| Jun 30, 2022 | 30.40% |
| Mar 31, 2022 | 28.57% |
| Dec 31, 2021 | 37.10% |
| Sep 30, 2021 | 37.69% |
| Jun 30, 2021 | 34.88% |